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Abstract
Background: Metabolic Syndrome (MetS) results from the combined effect of environmental and genetic factors.
We investigated the possible association of peroxisome proliferator-activated receptor-g2 (PPARg2) Pro12Ala and
Angiotensin Converting Enzyme (ACE) I/D polymorphisms with MetS and interaction between these genetic
variants.
Methods: Three hundred sixty four unrelated Caucasian subjects were enrolled. Waist circumference, blood
pressure, and body mass index (BMI) were recorded. Body composition was estimated by impedance analysis; MetS
was diagnosed by the NCEP-ATPIII criteria. A fasting blood sample was obtained for glucose, insulin, lipid profile
determination, and DNA isolation for genotyping.
Results: The prevalence of MetS did not differ across PPARg2 or ACE polymorphisms. Carriers of PPARg2 Ala allele
had higher BMI and fat-mass but lower systolic blood pressure compared with Pro/Pro homozygotes. A significant
PPARg2 gene-gender interaction was observed in the modulation of BMI, fat mass, and blood pressure, with
significant associations found in women only. A PPARg2-ACE risk genotype combination for BMI and fat mass was
found, with ACE DD/PPARg2 Ala subjects having a higher BMI (p = 0.002) and Fat Mass (p = 0.002). Pro12Ala was
independently associated with waist circumference independent of BMI and gender.
Conclusions: Carriers of PPARg2 Ala allele had higher BMI and fat-mass but not a worse metabolic profile, possibly
because of a more favorable adipose tissue distribution. A gene interaction exists between Pro12Ala and ACE I/D
on BMI and fat mass. Further studies are needed to assess the contribution of Pro12Ala polymorphism in adiposity
distribution.
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Background
Epidemiological studies have demonstrated that glucose
intolerance, hypertension, and abdominal obesity often
coexist in the same individuals increasing the risk for
coronary heath disease (CHD). In 1988, Reaven focused
on this cluster of cardiovascular risk factors, named it as
“syndrome X”, and proposed insulin resistance as the
possible common etiological factor [1]. The relationship
between insulin resistance and metabolic risk factors is
not fully understood and appears complex. Most per-
sons with insulin resistance have abdominal obesity, and
dysfunctional adipose tissue might be the common link
in determining this cluster of risk factors, currently
named as metabolic syndrome (MetS).
Among the clinical criteria proposed for the diagnosis
of MetS, the one provided by the National Cholesterol
Education Program-Adult Treatment Panel III (NCEP-
ATPIII) is easily applicable, and identifies patients with
different combinations of hypertension, atherogenic dys-
lipidemia, impaired glucose homeostasis, and visceral
obesity [2]. It is difficult to dissect the possible
* Correspondence: psn@unife.it
† Contributed equally
Department of Clinical and Experimental Medicine, Section of Internal
Medicine, Gerontology and Clinical Nutrition, University of Ferrara, Ferrara,
Italy
Passaro et al. Cardiovascular Diabetology 2011, 10:112
http://www.cardiab.com/content/10/1/112
CARDIO
VASCULAR 
DIABETOLOGY
© 2011 Passaro et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.contribution of each MetS component to CHD risk;
however, there is little doubt that in individuals with
MetS the CHD risk is increased, and that insulin resis-
tance enhances the risk of developing type 2 diabetes.
The pathogenesis of MetS has been associated with
the effect of a genetic predisposition [3] in combination
with environmental factors. Considering the central role
of adipose tissue in MetS, different adipocyte related
genes have been studied as possible candidates in MetS,
including peroxisome proliferator-activated receptor-g
(PPARg), and renin-angiotensin system related genes.
PPARg transcriptionally regulates the expression of
genes involved in cell metabolism; endogenous ligands
are thought to bind PPARg and promote downstream
gene target transcription [4,5]. From human PPARg
gene two distinct isoforms of mRNA and protein,
PPARg1 and PPARg2, are spliced [6]. PPARg 1i sa b u n -
dantly expressed in different tissues including adipose
tissue and macrophages [7], whereas PPARg 2e x p r e s -
sion is restricted only to adipose tissue. In vivo and in
vitro studies demonstrated that PPARg has a critical role
in regulating adipocyte differentiation and lipid accumu-
lation [8,9]; furthermore, its has been implicated in the
regulation of lipid homeostasis and insulin sensitivity
[10]. Not surprisingly, PPARg has been identified as the
target for thiazolidinediones [11], drugs that improve
insulin sensitivity [10]. The role of PPARg in affecting
insulin action has been confirmed by several genetic stu-
dies on PPARg gene polymorphisms; among these, the
Pro12Ala mutation in PPARg 2 (Pro12Ala) is the most
common [12]. The Ala12 variant has been associated
with decreased body mass index (BMI) [13-16],
increased BMI [17,18], and increased risk of obesity
[19]. Different meta-analysis on Pro12Ala mutation and
type 2 diabetes indicates that Ala12 carriers have a
reduced risk of diabetes compared to Pro12 carriers
[20,21]; nevertheless, the association between Pro12Ala
and type 2 diabetes seems to be modulated by genetic
and environmental factors, dietary lipids [22], and
intrauterine condition [23].
Recently, the Angiotensin Converting Enzyme (ACE)
gene also received substantial attention as possible can-
didate for diabetes [24], hypertension [25], cardiovascu-
lar disease [26], and diabetic nephropathy [27]. Recent
data suggest that the Renin Angiotensin System might
be involved in the pathophysiology of obesity and asso-
ciated hypertension [28]; therefore, ACE gene might be
a good candidate for MetS. The most common ACE
gene polymorphism is the insertion-deletion (I/D)
located in intron 16; the D allele has been associated
with higher levels of circulating ACE [29,30]. Moreover
PPARs modulate the renin-angiotensin-aldosterone sys-
tem (RAAS), by transcriptional control of renin, angio-
tensinogen, angiotensin converting enzyme (ACE) and
angiotensin II receptor 1 (AT-R1) [31], linking biologi-
cally the Renin Angiotensin System with the PPARs.
Despite data on the association between ACE gene and
MetS or hypertension are not conclusive, it appears
interesting to evaluate the possible interaction of these
two common polymorphisms.
In the present study we investigated, in a cohort of
Italian adult individuals, the possible association
between PPARg2 Pro12Ala and ACE I/D polymorphisms
and MetS components; furthermore, we searched for a
possible interaction between these two common genetic
variants.
Methods
Subjects
From January 2007 to December 2008, 364 outpatients
consecutively referred to our clinic for metabolic disor-
ders, at the S. Anna University Hospital (Ferrara, Italy),
were enrolled. All patients were unrelated and Caucasian.
They underwent a complete medical interview and medi-
cal examination; arterial blood pressure was registered.
27.5% of subjects were taking antidiabetic drugs while 39%
were taking antihypertensive therapy. Their BMI was cal-
culated (Kg/m
2), and waist circumference was measured
between the lower rib and the iliac crest at the end of a
normal expiration. Body composition was estimated by
impedance analysis (Human IM plus II
®,D SM e d i c a ,
Milan, IT). After overnight fasting, a blood sample was
drawn for biochemical analysis and DNA extraction.
MetS components were diagnosed in accordance with
the NCEP-ATPIII criteria (2), assigning each subject an
individual score from 0 (no MetS features) to 5 (five
MetS features). Subjects having a score ≥3w e r ec o n s i d -
ered as affected by MetS. The Study was approved by
the local ethic committee and all participants gave their
written consent.
Biochemical analysis
Fasting glucose was assessed by glucose oxidase method
(Glucose Analyzer II, Beckmann Instruments, Fullerton,
CA, USA), while plasma total cholesterol and triglycerides
were evaluated by standard enzymatic techniques (Boeh-
ringer Mannheim-Diagnostica, Mannheim, Germany).
Low-density lipoprotein (LDL)-cholesterol was calculated
by the Friedewald formula. Serum concentrations of high-
density lipoprotein (HDL) cholesterol were measured after
precipitation of apoprotein B with phosphotungstic acid-
MgCl2 and by homogeneous method [10]. Fasting insulin
was measured by standard chemiluminescent assay
(Access System, Beckman, Palo Alto, CA, USA).
Genotyping
Genomic DNA was extracted from peripheral blood
using standard technique [32]. The Pro12Ala PPARg 2
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reaction-restriction fragment length polymorphism
(PCR-RFLP) analysis. The analysis, as previously
described [12], uses a mutagenic PCR primer to intro-
duce a BstU I restriction site only when a C ®G substi-
tution at nucleotide 34 of the PPARg 2g e n ei sp r e s e n t .
Genotyping was repeated in all Ala12 homozygotes, all
Pro12Ala heterozygotes, and in randomly selected Pro12
homozygotes; reproducibility was 100%.
A DNA fragment on intron 16 of the ACE gene was
amplified by PCR to determine the ACE I/D genotype
(rs4340). The sequences of flanking primers used were
5’-CTGGAGACCACTCCCATCCTTTCT-3’ for the
sense primer and 5’-GATGTGGCCATCA CATTCGT-
CAGAT-3’ for the antisense primer. PCR amplification
products were obtained as previously described [33]. To
avoid ID-DD mistyping, a pair of primers that amplify a
region inside intron 16 was also used to analyze all sam-
ples showing DD genotype [33].
Statistical analysis
Because of the low number of Ala/Ala homogygotes (n
= 5), Pro/Ala and Ala/Ala carriers were pooled together
in statistical analysis (named XA). Variables with normal
distribution are expressed as mean ± standard deviation
while variables with a not normal distribution are
expressed as median and interquartile range and were
log transformed before entering the statistical analysis.
Means were compared by ANOVA using the Bonferroni
Post Hoc Tests for post-hoc analysis, while medians
were compared by non-parametric tests (Kruskal Wallis
test). Correlations between continuous variables were
tested by multivariate linear regression analysis. The
prevalence of MetS among different genotypes was
tested by the Chi-square test.
To test the hypothesis that the relationship between
BMI and waist circumference might be different accord-
ing to PPARg2 genotype, we performed a 2 ways
ANOVA comparing slopes of the two regression lines.
The possible association between waist circumference
and other variables of interest (BMI, gender and
PPARg2polymorphism) was tested by multivariate linear
regression analysis.
Interaction between gene polymorphisms in modulat-
ing BMI and fat mass was tested by, age weighted, gen-
eral linear model univariate analysis.
All statistical tests were performed using SPSS 16.0
software (SPSS Inc., Chicago, IL).
Results
The principal clinical features of the whole sample
across different PPARg2 and ACE I/D genotypes are
reported in Table 1. We found 5 Ala/Ala subjects
(1.4%), 25 Pro/Ala subjects (7%) and 334 Pro/Pro sub-
jects (92%). Ala allele frequency appears to be consistent
with previous reports [34].
Compared with Pro/Pro homozygotes (PP), PPARg2
Ala carriers were characterized by higher BMI (p: 0.015)
and higher fat-mass (p:0.016), but lower systolic blood
pressure (p:0.033). No significant differences in waist cir-
cumference and other metabolic features were observed.
Subjects carrying different ACE polymorphisms did not
differ in terms of BMI, waist circumference, blood pres-
sure, fasting glucose-insulin levels, and lipid profile.
A significant PPARg2 gene-gender interaction was
observed in the modulation of BMI, fat-mass and
Table 1 Clinical features of the whole study population across different PPARg2 and ACE I/D genotypes
All subjects
Pro12Ala ACE I/D
PP (334) XA (30) p DD (137) ID (172) II (55) p
Age (years) 56 ± 13 53 ± 10 0.200 56 ± 12 55 ± 14 56 ± 13 0.805
BMI (kg/m2) 30.6 ± 5.7 33.2 ± 6.3 0.015 31.3 ± 6.3 30.4 ± 5.4 30.9 ± 5.5 0.402
WAIST (cm) 98.4 ± 13.9 100.1 ± 13.8 0.528 99.8 ± 14.5 97.5 ± 13.2 98.7 ± 14.2 0.360
Fat Mass (kg) 30.1 ± 11.9 35.7 ± 13.1 0.016 31.1 ± 12.8 29.9 ± 11.6 31.1 ± 12.2 0.644
Glucose (mmol/L) 6.5 ± 2.6 5.9 ± 2.3 0.271 6.7 ± 2.9 6.2 ± 2.3 6.5 ± 2.5 0.22
Insulin (μUI/L)* 7.8 (5.1-12.2) 10.1 (8.0-15.6) 0.284 8.0 (6.0-11.7) 7.9 (5.0-13.0) 8.9 (5.3-14.5) 0.338
HOMA Insulin Resistance* 2.1 (1.3-3.4) 2.3 (1.9-3.6) 0.668 2.1 (1.5-3.3) 2.1 (1.2-3.5) 2.4 (1.3 -3.9) 0.816
Systolic Blood Pressure (mmHg) 134.1 ± 17.4 126.8 ± 17.2 0.033 132.3± 17.1 134.7± 18.1 132.6± 16.3 0.486
Diastolic Blood Pressure (mmHg) 82.4 ± 8.5 81.6 ± 10.6 0.637 82.4 ± 9.2 82.6 ± 8.3 81.2 ± 8.5 0.612
Total Cholesterol (mmol/L) 5.6 ± 1.4 5.9 ± 1.1 0.245 5.8 ± 1.4 5.7 ± 1,4 5.3 ± 1,2 0.1
Triglyceride (mmol/L)* 1.46 (1.04-2.07) 1.32 (0.99-1.93) 0.566 1.54 (1.13-2.15) 1.4 (0.99-2.01) 1.43 (0.97-2.0) 0.41
HDL cholesterol (mmol/L) 1.3 ± 0.4 1.4 ± 0.3 0.595 1.3 ± 0.4 1.3 ± 0.4 1.4 ± 0.3 0.92
LDL Cholesterol (mmol/L) 3.5 ± 1.3 3.8 ± 1.1 0.199 3.6 ± 1.2 3.6 ± 1.3 3.2 ± 1.1 0.16
*Median (Interquartile range)
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was separately conducted by gender, XA women (but
not men) showed higher BMI (p: 0.029) and fat-mass (p:
0.028) compared with PP. Similarly, a trend toward
lower values of systolic blood pressure was observed in
XA women (but not men) compared with PP (p: 0.07).
The combined effect of PPARg-ACE genotypes on
BMI, fat-mass and waist circumference is shown in Fig-
ure 1. In individuals homozygous for ACE D allele,
t h o s eb e a r i n gaP P A R g Ala allele (XA/DD) showed
higher BMI (p:0.002) and higher fat-mass (p:0.002).
Figure 2 reports the two linear regressions for BMI vs
waist circumference according to PPARg2 Pro12Ala gen-
otypes (PP and XA). BMI correlated with waist circum-
ference in both group; however, the slope tend to be
lower in XA compared with PP individuals (Slope XA
1,817 ± 0,2275, slope PP 1,975 ± 0,07910, p:0.53).
By multivariate linear regression analysis we were able to
demonstrate that the PPARg2 Pro12Ala polymorphism (as
categorical variable: PP:0; XA:1) was significantly associated
with waist circumference (b coefficient: -2.73; p: 0.04) inde-
pendent of BMI (b coefficient: 2.03; p: 0.001), and gender
(b coefficient: 8.75; p: 0.001) (p for model: 0.001).
The number of MetS components was not different in
subjects carrying different PPARg2 or ACE ID genotypes
(Table 3). When subjects free from drug treatments
were analyzed separately, a lower prevalence of MetS
emerged in individuals bearing the ACE II genotype (p:
0.018).
Discussion
We evaluated the possible association between PPARg
pro12Ala and ACE I/D gene polymorphisms and MetS,
fat-mass, and fat distribution. As previously reported
[17,19,35], we found that carriers of the Ala allele had
higher BMI. Although some studies [13-16] have shown
Pro12Ala to be associated with lower BMI, our results
coincide with meta-analysis conducted by Masud et al.
[18] that found Ala allele association with higher BMI,
specifically in subject with mean BMI > 27, similar to
our population BMI. We also found a significant gene-
gender interaction with BMI and fat-mass significantly
higher in women but not men. This is in contrast with
t h ed a t ar e c e n t l yr e p o r t e db yM o r i n ie ta l .[ 3 6 ] ,i na
population with the same genetic background. We can-
not exclude that the lack of association in men might be
due to the limited number of males and the consequent
lack of statistical power.
Despite having higher BMI, XA subjects showed simi-
lar waist, fasting glucose, and fasting insulin compared
to PP subjects. Moreover XA individuals showed lower
systolic blood pressure. It appears from our data that
the increase in BMI associated with PPARg2A l ag e n o -
type was not associated with a worse metabolic profile.
We speculate that Ala genotype might reduce central fat
distribution thus protecting from metabolic complica-
tion associated with increased BMI. This would be in
good agreement with a previous report in a Spanish
population [37]. This hypothesis would be supported by
the finding that the regression between BMI and waist
had a lower slope in XA individuals; despite not being
significant. This result suggests that, for a given BMI,
subjects carrying the Ala allele might have less visceral
fat. Moreover, multiple regression analysis showed that
Pro12Ala polymorphism was an independent predictor
of waist circumference.
Several human and animal studies support a central
role of PPARg in adipose tissue distribution [38,39]. Ala
Table 2 Gender based dimorphism of PPARg2 gene polymorphism on clinical features of the study population
PPARg2 Pro12Ala
Men Women
PP (129) XA (8) p PP (205) XA (22) p
Age (years) 57 ± 14 57 ± 14 0.970 55 ± 13 51 ± 8 0.141
BMI (kg/m2) 29.98 ± 4.75 31.20 ± 6.69 0.492 30.98 ± 6.19 34.02 ± 6.16 0.029
WAIST (cm) 102.40 ± 12.76 104.19 ± 15.04 0.705 95.92 ± 14.05 98.61 ± 13.38 0.392
Fat Mass (kg) 27.35 ± 10.62 29.16 ± 13.56 0.646 31.88 ± 12.47 38.08 ± 12.42 0.028
Glucose (mmol/L) 7.1 ± 2.8 5.9 ± 2.1 0.278 6.1 ± 2.4 5.9 ± 2.4 0.737
Insulin (μUI/L)* 7.7 (5.2-12.0) 7.2 (4.0-14.4) 0.778 7.9 (5.1-12.6) 10.08 (8.6-15-7) 0.210
HOMA Insulin Resistance* 2.4 (1.5-3.5) 1.9 (0.9-3.6) 0.466 2.0 (1.3-3.3) 2.4 (2.1-3.6) 0.416
Systolic Blood Pressure (mmHg) 136.93 ± 15.09 134.17 ± 6.65 0.657 132.38 ± 18.51 124.77 ± 18.67 0.070
Diastolic Blood Pressure (mmHg) 82.57 ± 8.23 84.17 ± 7.36 0.642 82.33 ± 8.69 80.91 ± 11.41 0.485
Total Cholesterol (mmol/L) 5.5 ± 1.5 5.5 ± 1.0 0.939 5.7 ± 1.3 6.1 ± 1.1 0.206
Triglyceride (mmol/L)* 1.76 (1.12-2.5) 1.3(1.05-1.9) 0.414 1.37 (0.96-1.79) 1.32 (0.96-1.93) 0.687
HDL cholesterol (mmol/L) 1.2 ± 0.3 1.4 ± 0.3 0.155 1.4 ± 0.3 1.4 ± 0.4 0.463
LDL Cholesterol (mmol/L) 3.4 ± 1.4 3.4 ± 0.9 0.918 3.6 ± 1.2 4.0 ± 1.1 0.162
*Median (interquartile range)
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activity; this reduced activity has been considered pivotal
in reducing BMI and, ultimately, in the increasing insu-
lin sensitivity in subjects with Ala allele [15,22]. How-
ever, the relationship between PPARg activity and
insulin sensitivity is far from being linear, and does not
necessarily pass through quantitative modification of fat
mass. Mechanisms regulating energy balance and meta-
bolic profile involve complex interactions between
genetic, environmental and behavioral factors. Genotype
may predispose to site-specific adiposity, culminating in
a state of energy imbalance. PPARg appears to be a key
regulator of energy balance, with polymorphisms on the
PPARg gene linked to obesity and effects on body com-
position [40-42]. Humans harboring loss of function
PPARg mutation (P467L) show a pattern of lipodystro-
phy and are insulin resistant [39]. Qualitative adipose
tissue modification and altered adipose tissue distribu-
tion are key features in determining metabolic
abnormalities in these subjects. In this view, our data
support the idea that the increased BMI found in sub-
jects with Ala allele may not be detrimental, similarly to
what happens in TZD treated patients showing meta-
bolic improvements despite increased body weight.
Indeed, XA individuals had higher BMI but lower systo-
lic blood pressure and similar lipid profile compared to
PP subjects.
We couldn’t find any difference between subjects with
different ACE I/D polymorphism. Studies published so
far reported both an association with MetS/hypertension
or lack of association [43,44]. This inconstancy might
depend from ethnic background, type of population
(diabetic or no diabetic subjects), and diagnostic criteria
chosen to define MetS. The NCEP ATPIII criteria are
operatively simple to use. Nevertheless, individuals can
be classified as hypertensive or diabetic only on the
basis of the active use of antidiabetic or antihypertensive
drugs, including ACE inhibitors. These drugs might be a
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   Genotypes (number of individuals) 
PP/DD (118)  PP/ID (164)  PP/II (52)  XA/DD (20)  XA/ID (7)  XA/II (3) P  value 
BMI (kg/m2) a  30,6   0,5  30,2   0,5  30,5   0,8  34,9   1,3  30,0   2,2  30,0   3,4  0.002 
Fat Mass (Kg) a  29,6   1,1  29,3   0,9  29,9   1,7  39,0   2,7  29,7   4,7  28,0   7,2  0.002 
a  Weighted Least Squares Regression - Weighted by Age (years). 
BMI  Fat Mass 
Figure 1 Interaction analysis between PPARg2 Pro12Ala and ACE I/D polymorphisms on BMI and fat mass. In the graph BMI (left chart)
and Fat Mass (right chart) were plotted according to all 6 different genotype combination. In the lower panel Mean ± SD and p value for
univariate regression analysis, age weighted, are reported.
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gene polymorphism. When we selected only pharma-
cotherapy naives subjects, we found a significantly lower
prevalence of MetS in subjects carrying the ACE II com-
pared to DD genotype.
We also found a significant gene interaction between
ACE I/D and PPARg2 Pro12Ala polymorphism on BMI
and fat-mass, with subjects XA/DD being the ones with
higher values. This is not surprising as recent studies
showed a role of ACE gene in regulating body weight;
indeed, an ACE-/- knock out mouse had reduced fat-
mass and improved insulin sensitivity [45]. Moreover,
Eisenmann et al. recently reported that children harbor-
ing the DD polymorphism have an higher BMI com-
pared to II carriers [46]. From a mechanistic point of
view, ACE DD subjects have higher levels of plasma
E coefficient  SE  P 
PP  1,980 0,079  0,0001 
XA  1,821 0,228  0,0001 
Figure 2 Linear regression between BMI and waist circumference according to different PPARg2 Pro12 Ala genotype (subjects bearing
Ala allele: black circles; subjects Pro homozygotes: white circles).
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sin II which has been identified as a trophic factor in
the differentiation of preadipocytes to mature adipocytes
[47].
Limits of our study
We are aware of the limit of our study in term of sam-
ple size, especially when carrying out subgroups analysis
a n dt h a tw em u s tb ec a u t i o u sa b o u td r a w i n gf i r mc o n -
clusions before validating them in a different, larger
cohort.
Conclusions
In conclusion we found that, despite a lack of associa-
tion between Pro12Ala and ACE I/D polymorphism and
MetS diagnosis, subjects carrying a PPARg2 Ala allele
have higher BMI and fat-mass but do not have a worse
metabolic profile, probably because a more favorable
distribution of adipose tissue. Pro12Ala polymorphism
effect on BMI is not constant across gender, with signif-
icant association only foundi nw o m a n .I te x i s t sag e n e
interaction between the two common polymorphism
Pro12Ala and ACE I/D on BMI and fat mass. Further
studies are needed to assess the real contribution of the
PPARgPro12Ala polymorphism in determining adipose
tissue distribution.
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a
Metabolic syndrome (%) 53.3 53.4 0.57
b 58.7 51.5 45.5 0.20
b
PP (143) XA (18) DD (55) ID (84) II (22)
Not treated
(n 161)
Metabolic score (n) 2.01 ± 1.2 2.11 ± 1.1 0.74 2.11 ± 1.2 2.10 ± 1.2 1.55 ± 1 0.09
Metabolic syndrome (%) 33.6 38.9 0.42 42.9 34.9 9.1 0.018
b
a ANOVA.
b Chi-square analysis
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